Protalix Biotherapeutics Inc Share Price TEL AVIV STOCK EXCHANGE
Stocks
US74365A1016
Pharmaceuticals
| Market Cap | 20Cr 0 18Cr 17Cr 15Cr 28Cr 1.96TCr 29Cr 196.17Cr 77Cr 987.35Cr 77Cr 75Cr 3.27TCr | P/E 2026 * |
13.4x | P/E 2027 * | 46.2x |
|---|---|---|---|---|---|
| Enterprise Value | 20Cr 0 18Cr 17Cr 15Cr 28Cr 1.96TCr 29Cr 196.17Cr 77Cr 987.35Cr 77Cr 75Cr 3.27TCr | EV / Sales 2026 * |
2.56x | EV / Sales 2027 * | 3x |
| Free-Float |
96.12% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Protalix Biotherapeutics Inc
| 1 day | -1.13% |
| Manager | Title | Age | Since |
|---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 59 | 30/06/2019 |
Gilad Mamlok
DFI | Director of Finance/CFO | 57 | 24/08/2025 |
Ori Kalid
CTO | Chief Tech/Sci/R&D Officer | - | 01/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Amos Bar Shalev
BRD | Director/Board Member | 73 | 01/07/2008 |
Aharon Schwartz
BRD | Director/Board Member | 83 | 01/11/2014 |
Dror Bashan
BRD | Director/Board Member | 59 | 30/06/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.13% | -11.89% | - | - | 20Cr | |
| -0.13% | -6.44% | +60.34% | +112.06% | 1,04700Cr | |
| +0.85% | -0.81% | +51.29% | +63.13% | 65TCr | |
| -1.03% | -3.58% | +21.43% | +73.10% | 45TCr | |
| -1.46% | -4.50% | +37.80% | +37.41% | 35TCr | |
| -0.72% | -2.89% | +22.32% | +36.62% | 29TCr | |
| -1.19% | -2.21% | +1.53% | +10.79% | 25TCr | |
| -1.05% | -1.57% | +50.30% | +66.55% | 23TCr | |
| +0.08% | -1.78% | -17.64% | -54.36% | 20TCr | |
| -2.14% | -0.30% | +28.95% | +86.27% | 18TCr | |
| Average | -0.79% | -2.68% | +28.48% | +47.95% | 40.66TCr | |
| Weighted average by Cap. | -0.46% | -3.46% | +38.17% | +65.00% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.98Cr 0 6.88Cr 6.45Cr 5.89Cr 11Cr 762.64Cr 11Cr 76Cr 30Cr 384.98Cr 30Cr 29Cr 1.28TCr | 6.82Cr 0 5.88Cr 5.51Cr 5.03Cr 9.47Cr 651.76Cr 9.5Cr 65Cr 26Cr 329.01Cr 26Cr 25Cr 1.09TCr |
| Net income | 1.54Cr 0 1.32Cr 1.24Cr 1.13Cr 2.14Cr 146.95Cr 2.14Cr 15Cr 5.75Cr 74Cr 5.77Cr 5.65Cr 245.96Cr | 44.63L 0 38.46L 36.06L 32.92L 62.01L 43Cr 62.21L 4.28Cr 1.67Cr 22Cr 1.68Cr 1.64Cr 71Cr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
